Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08HWV
|
|||
| Drug Name |
BGB-A317
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 3 | [1] | |
| Squamous cell carcinoma [ICD-11: 2B60-2D01; ICD-10: C44; ICD-9: 199] | Phase 3 | [1] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [2] | ||
| Company |
BeiGene Cambridge, MA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death protein 1 (PD-1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Reactome | PD-1 signaling | |||
| WikiPathways | T-Cell Receptor and Co-stimulatory Signaling | |||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.